Verify any claim · lenz.io
“In the Phase 3 SURMOUNT-1 trial, participants received once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks.”
The conclusion
The claim accurately describes the treatment arms and primary duration of SURMOUNT-1. The primary NEJM report, study protocol and trial registry confirm that this phase 3 trial assigned participants to once-weekly subcutaneous tirzepatide at target doses of 5 mg, 10 mg or 15 mg, or placebo, over 72 weeks.
Caveats
- The listed doses were assigned target doses; treatment started at 2.5 mg and increased during a dose-escalation period of up to 20 weeks included within the 72 weeks.
- Participants with prediabetes had a treatment extension to 176 weeks; the claim describes the primary 72-week period.
- The protocol and registry describe the same Lilly-sponsored trial and are not independent replications of its findings.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Check facts and citations in the tools you already use
Connect Lenz to ChatGPT, Claude, or WhatsApp and check a claim mid-conversation.
Or create a free account to bookmark this verification and run your own checks.
Sources
Ranked by source quality and relevance
In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. … After a 2-week screening period, participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention.Methods In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. … ### Procedures After a 2-week screening period, participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. Lifestyle intervention included regular lifestyle counseling sessions, delivered by a dietitian or a qualified health care professional, to help the participants adhere to healthful, balanced meals, with a deficit of 500 calories per day, and at least 150 minutes of physical activity per week.
Now, the SURMOUNT-1 study, a phase III double-blind randomised control trial published in The New England Journal of Medicine, has examined the safety and efficacy of tirzepatide for weight loss in people without diabetes mellitus. Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide once-weekly at a 5 mg, 10 mg or 15 mg dose or placebo for 72 weeks.- Olivia Tysoe 1 Tirzepatide is a novel glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. A previous phase II study in people with type 2 diabetes mellitus (T2DM) suggested that tirzepatide could induce clinically significant weight loss (≥5 kg). Now, the SURMOUNT-1 study, a phase III double-blind randomised control trial published in The New England Journal of Medicine, has examined the safety and efficacy of tirzepatide for weight loss in people without diabetes mellitus. Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide once-weekly at a 5 mg, 10 mg or 15 mg dose or placebo for 72 weeks. Participants were also required to maintain a healthy diet with a 500 calorie deficit per day and undertake a minimum of 150 minutes of physical activity per week. The primary endpoints of the trial were percentage change in body weight from baseline and a weight reduction of ≥5% at week 72. This is a preview of subscription content, access via your institution
Study GPHK (SURMOUNT-1) is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI ≥30 kg/m 2) or overweight (≥27 kg/m 2 ) with at least one weight-related comorbid condition … Beginning at randomization, all participants will receive study drug according to the randomized treatment arm for the duration of the 72-week treatment period including a 20-week dose escalation.LY3298176 37 4. Study Design 4.1. Overall Design Study GPHK (SURMOUNT-1) is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI ≥30 kg/m 2) or overweight (≥27 kg/m 2 ) with at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). The coprimary endpoints will be mean percent change in weight and percentage of participants reaching ≥5% total body weight loss, measured from randomization to Week 72. Study participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men. … standards, to set lifestyle goals for caloric intake and physical activity (Sections 5.3.1 and 5.3.2). Following randomization, study site personnel will demonstrate use of the autoinjector (also referred to as single-dose pen) using the provided demonstration device and observe the study participant inject the first dose of tirzepatide or placebo. The date, time, and location of the first dose of study drug will be recorded on the electronic case report form (eCRF). Beginning at randomization, all participants will receive study drug according to the randomized treatment arm for the duration of the 72-week treatment period including a 20-week dose escalation. Participants will be provided diaries and be trained to record key study information, as appropriate. Treatment Period (End of Visit 3 to Visit 21): During the treatment period, office visits will occur monthly through 24 weeks and then every 12 weeks thereafter, to 72 weeks. The participant should be fasting for all office visits. Telephone visits will occur at 4-week intervals between the office visits starting at Week 28.
Briefly, SURMOUNT‐1 was a phase 3, multicenter, randomized, placebo‐controlled, double‐blind study of the safety and efficacy of once‐weekly tirzepatide compared with placebo for weight management when used in conjunction with a reduced‐calorie diet and increased physical activity. After a 2‐week screening period, participants were randomized 1:1:1:1 to receive once‐weekly tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo. … For participants randomly assigned to receive tirzepatide, the starting dose was 2.5 mg once weekly via subcutaneous injection. The dosage was increased in 2.5‐mg increments every 4 weeks until the assigned study dose was achieved (5, 10, or 15 mg). The dose‐escalation period continued for up to 20 weeks. Participants in the placebo group received a matching once‐weekly placebo. After randomization, participants completed the 72‐week treatment period.Trial Design and Procedures A full description of the study design and outcomes of the SURMOUNT‐1 trial has been published [11]. Briefly, SURMOUNT‐1 was a phase 3, multicenter, randomized, placebo‐controlled, double‐blind study of the safety and efficacy of once‐weekly tirzepatide compared with placebo for weight management when used in conjunction with a reduced‐calorie diet and increased physical activity. After a 2‐week screening period, participants were randomized 1:1:1:1 to receive once‐weekly tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo. A computer‐generated random sequence using an interactive web‐response system randomly assigned participants to treatment groups, with randomization stratified by participants' prediabetes status, country, and sex. For participants randomly assigned to receive tirzepatide, the starting dose was 2.5 mg once weekly via subcutaneous injection. The dosage was increased in 2.5‐mg increments every 4 weeks until the assigned study dose was achieved (5, 10, or 15 mg). The dose‐escalation period continued for up to 20 weeks. Participants in the placebo group received a matching once‐weekly placebo. After randomization, participants completed the 72‐week treatment period. Participants with prediabetes at randomization completed an additional 2‐year treatment period, whereas participants without prediabetes proceeded to a 4‐week safety follow‐up period. Participants were advised to undergo a lifestyle intervention comprising a hypocaloric diet with a 500‐cal deficit that was individually calculated and an increase in physical activity by 150 min per week. Lifestyle counseling was administered throughout the entire study.
SM‐1 and SM‐2 were phase 3, multicentre, randomized, placebo‐controlled, double‐blind trials evaluating the safety and efficacy of tirzepatide in individuals with obesity or overweight, without (SM‐1) or with T2D (SM‐2). … Tirzepatide 2.5 mg (or matching placebo) was initiated once a week, and dose escalated every 4 weeks until the randomized dose of 5, 10 or 15 mg in SM‐1 and 10 or 15 mg in SM‐2 was achieved and continued until Week 72.… Early response to weight loss interventions may help optimize achievement of individual treatment goals. Tirzepatide has demonstrated significant weight reduction and improvement in cardiometabolic risk parameters (CRPs) in the SURMOUNT (SM)‐1 (NCT04184622) and SM‐2 (NCT04657003) trials. We aimed to assess weight reduction, CRPs, tolerability and hypoglycaemia according to early body weight response to tirzepatide in these studies. SM‐1 and SM‐2 were phase 3, multicentre, randomized, placebo‐controlled, double‐blind trials evaluating the safety and efficacy of tirzepatide in individuals with obesity or overweight, without (SM‐1) or with T2D (SM‐2). Post hoc exploratory analyses included tirzepatide‐treated participants from SM‐1 (n = 1775) and SM‐2 (n = 609), categorized as early responders (ERs; ≥ 5% weight reduction) or nonearly responders (non‐ERs; < 5% weight reduction) at Week 8. Outcomes were assessed using the efficacy estimand with logistic regression and mixed models for repeated measures. Across both studies (N = 2384), ERs were more likely to be female, White and to have lower baseline HbA1c levels. … Of note, in SM‐1, participants without T2D and with a body mass index (BMI) ≥ 30 kg/m<sup>2</sup> or ≥ 27 kg/m<sup>2</sup> and at least one weight‐related complication (e.g., hypertension or dyslipidemia) were included [6]. In SM‐2, participants with T2D, a BMI ≥ 27 kg/m<sup>2</sup> and glycated haemoglobin (HbA1c) of 7%–10% under stable antihyperglycemic therapy for ≥ 3 months before screening were included [6]. Tirzepatide 2.5 mg (or matching placebo) was initiated once a week, and dose escalated every 4 weeks until the randomized dose of 5, 10 or 15 mg in SM‐1 and 10 or 15 mg in SM‐2 was achieved and continued until Week 72. The protocols were approved by local institutional review boards, and the trials were conducted in accordance with the Declaration of Helsinki, the Council of International Organizations of Medical Sciences International Ethical Guidelines and Good Clinical Practice guidelines. All participants provided written informed consent.
Briefly, SURMOUNT-1, a phase 3, randomized, double-blind, placebo-controlled study, included adults (age ≥18 years) with obesity (body mass index [BMI] ≥30 kg/m 2) or overweight (BMI ≥27 kg/m 2 and at least one weight related complication) without diabetes. Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5, 10 or 15 mg, or placebo, administered subcutaneously once weekly for 72 weeks in combination with lifestyle intervention.This was a post hoc analysis of the SURMOUNT-1 clinical trial using patient-level data to compare the percent change in risk for long-term ASCVD outcomes from baseline up to 72 weeks between tirzepatide and placebo-treated groups. Details of the SURMOUNT-1 study design have been published previously. 27 Briefly, SURMOUNT-1, a phase 3, randomized, double-blind, placebo-controlled study, included adults (age ≥18 years) with obesity (body mass index [BMI] ≥30 kg/m 2) or overweight (BMI ≥27 kg/m 2 and at least one weight related complication) without diabetes. Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5, 10 or 15 mg, or placebo, administered subcutaneously once weekly for 72 weeks in combination with lifestyle intervention. Tirzepatide treat ment was initiated at 2.5 mg and escalated every 4 weeks in 2.5-mg increments during the dose-escalation period. The original SURMOUNT-1 trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
The primary study period of SURMOUNT‐1 (NCT04184622) was completed and included 2539 adults without diabetes. Participants were randomized in a 1:1:1:1 ratio to tirzepatide (5, 10, or 15 mg) or placebo to study the effects of tirzepatide on CWM (Figure 1, Table 1). … All randomized participants were planned to undergo a 72‐week treatment period (primary study period) that included a dose‐escalation period of up to 20 weeks and allowed for 52 weeks of follow‐up on the highest dose (15 mg). … FIGURE 1 SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, placebo‐controlled, double‐blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced‐calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity‐related complications (excluding type 2 diabetes).Study design The primary study period of SURMOUNT‐1 (NCT04184622) was completed and included 2539 adults without diabetes. Participants were randomized in a 1:1:1:1 ratio to tirzepatide (5, 10, or 15 mg) or placebo to study the effects of tirzepatide on CWM (Figure 1, Table 1). Randomization was stratified by country, sex, and glycemic status (normoglycemia vs. prediabetes) as defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes [32]. All randomized participants were planned to undergo a 72‐week treatment period (primary study period) that included a dose‐escalation period of up to 20 weeks and allowed for 52 weeks of follow‐up on the highest dose (15 mg). A subset of participants (n = 255) underwent further assessment to evaluate effects of tirzepatide on body composition. Heart rate and blood pressure were assessed in more detail in an additional subset of participants owing to potential effects of GLP‐1 receptor agonists on hemodynamics. *FIGURE 1 SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, placebo‐controlled, double‐blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced‐calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity‐related complications (excluding type 2 diabetes).*Participants who had prediabetes at randomization but discontinued the study during the 72‐week treatment period were included in the 4‐week safety follow‐up. QW, once weekly*
In a study from 2022, 2500 adults without diabetes but with obesity (body-mass index [BMI] ≥30 kg/m 2 or BMI ≥27 with at least one weight-related complication) were randomized to lifestyle modification plus subcutaneous tirzepatide (at doses of 5 mg, 10 mg, or 15 mg weekly) or placebo for 72 weeks, including a 20-week dose-escalation period.Subcutaneous tirzepatide (Mounjaro), a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor agonist, is U.S. FDA approved for use at doses as high as 15 mg weekly for treating patients with type 2 diabetes. Two large trials now have demonstrated its effectiveness for treating patients with obesity. In a study from 2022, 2500 adults without diabetes but with obesity (body-mass index [BMI] ≥30 kg/m 2 or BMI ≥27 with at least one weight-related complication) were randomized to lifestyle modification plus subcutaneous tirzepatide (at doses of 5 mg, 10 mg, or 15 mg weekly) or placebo for 72 weeks, including a 20-week dose-escalation period. The mean percentage changes in weight were −15%, −20%,…
In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. … We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo.Background Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. Methods We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods.
SURMOUNT‐1 and ‐4 were phase 3, double‐blind, randomized, placebo‐controlled trials evaluating the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one adiposity‐related complication, who did not have diabetes. … The primary study period of SURMOUNT‐1 included a 2‐week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo.Study design of the phase 3 trials SURMOUNT‐1 and ‐4 were phase 3, double‐blind, randomized, placebo‐controlled trials evaluating the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one adiposity‐related complication, who did not have diabetes. <sup>11</sup> The primary study period of SURMOUNT‐1 included a 2‐week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo. SURMOUNT‐4 included a 2‐week screening period, followed by 36 weeks of open‐label tirzepatide treatment to achieve a maximum tolerated dose (MTD) of 10 or 15 mg, followed by randomization to a 52‐week treatment period of either continuing tirzepatide treatment or switching to placebo.
Participants were randomized for at least 72 weeks (14 visits) to receive tirzepatide at doses of 5 mg (n = 630), 10 mg (n = 636), and 15 mg (n = 630) once weekly (with an initial dose of 2.5 mg to the target dose by Week 20 of the study, in line with the Summary of Product Characteristics) [21] along with a reduced-calorie diet and increased physical activity for weight management. … At 72 weeks, the mean change in body weight observed for patients receiving placebo was − 2.4% (95% CI, − 3.2 to − 1.6), a reduction of 2.4 kg (5.3 lb) [22].SURMOUNT-1 participants (N = 2539) were adults (from nine countries across four continents: Argentina, Brazil, China, India, Japan, Mexico, Russian Federation, Taiwan, and the US) without type 2 diabetes who had obesity (BMI ≥ 30 kg/m<sup>2</sup>) or were overweight (BMI ≥ 27 kg/m<sup>2</sup>) with at least one weight-related issue and at least one unsuccessful dietary effort to lose weight. Participants were randomized for at least 72 weeks (14 visits) to receive tirzepatide at doses of 5 mg (n = 630), 10 mg (n = 636), and 15 mg (n = 630) once weekly (with an initial dose of 2.5 mg to the target dose by Week 20 of the study, in line with the Summary of Product Characteristics) [21] along with a reduced-calorie diet and increased physical activity for weight management. Those participants identified as having prediabetes continued for another 2 years to assess the percentage change in body weight and the onset of type 2 diabetes at 176 and 193 weeks. At 72 weeks, the mean change in body weight observed for patients receiving placebo was − 2.4% (95% CI, − 3.2 to − 1.6), a reduction of 2.4 kg (5.3 lb) [22]. Given that this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, ethics committee approval was not required. The SURMOUNT-1 study received the necessary ethical approvals from all study sites, obtained informed patient consent to participate, and was conducted in accordance with the Declaration of Helsinki. Cost Analysis
SURMOUNT‐1 and ‐4 were phase 3, double‐blind, randomized, placebo‐controlled trials evaluating the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one adiposity‐related complication, who did not have diabetes. 11 The primary study period of SURMOUNT‐1 included a 2‐week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo.Study design of the phase 3 trials SURMOUNT‐1 and ‐4 were phase 3, double‐blind, randomized, placebo‐controlled trials evaluating the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one adiposity‐related complication, who did not have diabetes. 11 The primary study period of SURMOUNT‐1 included a 2‐week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo. SURMOUNT‐4 included a 2‐week screening period, followed by 36 weeks of open‐label tirzepatide treatment to achieve a maximum tolerated dose (MTD) of 10 or 15 mg, followed by randomization to a 52‐week treatment period of either continuing tirzepatide treatment or switching to placebo.
After screening, eligible participants are randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly by subcutaneous injection using an autoinjector. All participants receive lifestyle counseling focused on a reduced-calorie diet and increased physical activity. The main treatment period is 72 weeks.Detailed Description After screening, eligible participants are randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly by subcutaneous injection using an autoinjector. All participants receive lifestyle counseling focused on a reduced-calorie diet and increased physical activity. The main treatment period is 72 weeks. Participants identified with prediabetes at randomization can continue study treatment for up to 176 weeks (plus follow-up), allowing evaluation of longer-term weight management and time to onset/progression to type 2 diabetes. Safety is monitored throughout, including adverse events and laboratory testing. Conditions
SURMOUNT‐1 (NCT04184622) was a 72‐week, phase 3, multicentre, randomised, placebo‐controlled, double‐blinded study that evaluated the safety and efficacy of 5, 10, and 15 mg tirzepatide once weekly, compared with placebo, when used in conjunction with a reduced‐calorie diet and increased physical activity for weight management.Study design SURMOUNT‐1 (NCT04184622) was a 72‐week, phase 3, multicentre, randomised, placebo‐controlled, double‐blinded study that evaluated the safety and efficacy of 5, 10, and 15 mg tirzepatide once weekly, compared with placebo, when used in conjunction with a reduced‐calorie diet and increased physical activity for weight management. Entry criteria and study design have been previously reported. <sup>1</sup> The 72‐week treatment period included an up to 20‐week dose‐escalation period up to the assigned dose, as previously described. …
The SURMOUNT-1 trial was a phase 3, multicenter, double-blind, placebo-controlled trial at 119 sites in nine countries. Patients were randomized in 1:1:1:1 fashion to tirzepatide 5 mg (n = 630), 10 mg (n = 636), or 15 mg (n = 630); or placebo (n = 643) administered subcutaneously once weekly for 72 weeks in addition to lifestyle intervention.Study Design The SURMOUNT-1 trial was a phase 3, multicenter, double-blind, placebo-controlled trial at 119 sites in nine countries. Patients were randomized in 1:1:1:1 fashion to tirzepatide 5 mg (n = 630), 10 mg (n = 636), or 15 mg (n = 630); or placebo (n = 643) administered subcutaneously once weekly for 72 weeks in addition to lifestyle intervention. Tirzepatide was initiated at 2.5 mg weekly and increased by 2.5 mg every 4 weeks. - Total enrolled participants: 2,539 - Median duration of follow-up: 72 weeks - Mean patient age: 44.9 years - Percentage female: 67.5% - White race: 70.6%
In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. … In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.)METHODS In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS … ## CONCLUSIONS In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.)
In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. … We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo.Abstract Background: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. Methods: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods.
The patients were randomized to receive 5, 10, or 15 mg of tirzepatide or matching placebo injection once weekly. Approximately 86% of participants completed the 72-week study. … Reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.… The study identified adults with a body mass index greater than 30.0 kg per m 2 or greater than 27.0 kg per m 2 with at least one weight-related complication, such as hypertension, sleep apnea, cardiovascular disease, or dyslipidemia. Patients with diabetes were excluded. The mean age of the 2,539 patients was 45 years, 67% were women, and 60% had a body mass index greater than 35.0 kg per m 2. Allocation concealment was not described, but groups were balanced at the start of the study. The patients were randomized to receive 5, 10, or 15 mg of tirzepatide or matching placebo injection once weekly. Approximately 86% of participants completed the 72-week study. The reduction in weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group. Reductions also occurred in metabolic markers, such as systolic blood pressure (6.2 mm Hg) and low-density lipoprotein cholesterol (4.2 mg per dL [0.15 mmol per L]), in the tirzepatide groups. Serious adverse events were rare and evenly distributed among groups. … Setting: Outpatient (any) Reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Editor's Note: Dr. Ebell is deputy editor for evidence-based medicine for AFP and cofounder and editor-in-chief of Essential Evidence Plus, published by Wiley-Blackwell.
In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. … In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).Background: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. Methods: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. Results: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. … Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. Conclusions: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.). - Shifting Tides Offer New Hope For Obesity.
- Official title: Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) … - Phase: PHASE3 … ### Placebo (PLACEBO_COMPARATOR) * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received once weekly (QW) subcutaneous (SC) doses of a matching placebo, administered over a period of 72 weeks.A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight - NCT ID: NCT04184622 - Official title: Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) - Acronym: SURMOUNT-1 - Organization: Eli Lilly and Company - Status: COMPLETED - Start date: 2019-12-04 - Completion date: 2024-07-06 - Primary completion: 2022-04-01 - Lead sponsor: Eli Lilly and Company Summary … ## Study Design - Study type: INTERVENTIONAL - Phase: PHASE3 - Enrollment: 2539 (ACTUAL) - Allocation: RANDOMIZED - Intervention model: PARALLEL - Primary purpose: TREATMENT - Masking: DOUBLE Arms Placebo (PLACEBO_COMPARATOR) * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received once weekly (QW) subcutaneous (SC) doses of a matching placebo, administered over a period of 72 weeks. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the placebo dose SC QW until week 176. …
Study I8F-MC-GPHK (GPHK; SURMOUNT-1) is a Phase 3, multicenter, randomized, placebo controlled, double-blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced-calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least 1 weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction.LY3298176 5. Study Design 5.1. Summary of Study Design Study I8F-MC-GPHK (GPHK; SURMOUNT-1) is a Phase 3, multicenter, randomized, placebo controlled, double-blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced-calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least 1 weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow-up time to detect potential differences in progression to T2DM. LY3298176
SURMOUNT‐1 was a phase 3, randomized, double blind, placebo‐controlled trial in adults with a body mass index (BMI) ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> with at least one weight‐related complication, excluding diabetes. Participants were assigned to receive once weekly tirzepatide or placebo. … Tirzepatide or placebo was initiated at a dose of 2.5 mg once weekly and was increased in 2.5 mg increments every 4 weeks through the 20‐week dose escalation period. Target dose was achieved at Week 4 (5 mg), Week 12 (10 mg) or Week 20 (15 mg) based on the randomized allocation.MATERIALS AND METHODS SURMOUNT‐1 was a phase 3, randomized, double blind, placebo‐controlled trial in adults with a body mass index (BMI) ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> with at least one weight‐related complication, excluding diabetes. Participants were assigned to receive once weekly tirzepatide or placebo. All participants received regular lifestyle counselling from a dietitian or qualified health professional to help them adhere to healthful, balanced meals, with a deficit of 500 calories per day and at least 150 minutes of physical activity per week. Tirzepatide or placebo was initiated at a dose of 2.5 mg once weekly and was increased in 2.5 mg increments every 4 weeks through the 20‐week dose escalation period. Target dose was achieved at Week 4 (5 mg), Week 12 (10 mg) or Week 20 (15 mg) based on the randomized allocation. The trial protocol and results have been previously published. <sup>6</sup> The trial adhered to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines, receiving approval from an independent ethics committee or institutional review board at each trial site. All participants provided written informed consent prior to participation in the study.
SURMOUNT-1 was the industry-sponsored trial that led to U.S. FDA approval of tirzepatide — branded as Zepbound — for managing obesity (NEJM JW Gen Med Aug 1 2023 and N Engl J Med 2022; 387:205). … The 1032 patients with prediabetes and obesity were randomized to one of three target doses of tirzepatide (5, 10, or 15 mg weekly) or placebo.During a 3-year study, most patients reverted to normoglycemia. SURMOUNT-1 was the industry-sponsored trial that led to U.S. FDA approval of tirzepatide — branded as Zepbound — for managing obesity (NEJM JW Gen Med Aug 1 2023 and N Engl J Med 2022; 387:205). Although the trial excluded patients with diabetes, 40% of participants had prediabetes. Now, the researchers report outcomes for the prediabetes subgroup, focusing on changes in glycemic status. The 1032 patients with prediabetes and obesity were randomized to one of three target doses of tirzepatide (5, 10, or 15 mg weekly) or placebo. Participants also received counseling on diet and physical activity — initially monthly, then quarterly. At 3 years, the following outcomes were noted: - Mean body weight (107 kg at baseline) decreased by 12% to 20% acr…
SURMOUNT-1 and -4 were phase 3, double-blind, randomized, placebo-controlled trials evaluating the efficacy and safety of tirzepa tide in adults with obesity or overweight and at least one adiposity related complication, who did not have diabetes. 11 The primary study period of SURMOUNT-1 included a 2-week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo.2.1 | Study design of the phase 3 trials SURMOUNT-1 and -4 were phase 3, double-blind, randomized, placebo-controlled trials evaluating the efficacy and safety of tirzepa tide in adults with obesity or overweight and at least one adiposity related complication, who did not have diabetes. 11 The primary study period of SURMOUNT-1 included a 2-week screening period followed by randomization (1:1:1:1) to 72 weeks of treatment with tirzepatide 5, 10, or 15 mg, or placebo. SURMOUNT-4 included a 2-week screen ing period, followed by 36 weeks of open-label tirzepatide treatment to achieve a maximum tolerated dose (MTD) of 10 or 15 mg, followed by randomization to a 52-week treatment period of either continuing tirzepatide treatment or switching to placebo. …
SURMOUNT-1 is the first investigational phase 3 trial evaluating the safety and efficacy of the novel once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist for the treatment of obesity. … Individuals were assigned in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period.* Individuals with **overweight ** or obesity taking tirzepatide lost up to 22.5% of their baseline body weight, according to findings from the SURMOUNT-1 trial, presented at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA. The results were published simultaneosly in the New England Journal of Medicine. *** SURMOUNT-1 is the first investigational phase 3 trial evaluating the safety and efficacy of the novel once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist for the treatment of obesity. “These results are an important step forward in potentially expanding effective therapeutic options for people with obesity. Notably, about 9 out of 10 individuals with obesity lost weight while taking tirzepatide,” said Ania Jastreboff, MD, PhD, associate professor Yale University School of Medicine, director of Weight Management and Obesity Prevention at the Yale Stress Center and co-director of the Yale Center for Weight Management, New Haven, Connecticut, in an ADA press statement. … Among the secondary endpoints of interest were absolute change in body weight from baseline, percentage of participants who achieve weight reduction of ≥10%, ≥15%, and ≥20%, and change in waist circumference and BMI. In total, 2539 participants with obesity or overweight met the SURMOUNT-1 inclusion criteria and were included in the final analyses. Individuals were assigned in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. **SURMOUNT-1 findings **
SURMOUNT-1 was a 72-week, double-blind, placebo-controlled, phase 3 trial that randomized 2539 adult patients with a body mass index (BMI) of ≥30 kg/m 2 or ≥27 kg/m 2 and at least 1 weight-related comorbid condition (study excluded patients with type I diabetes or type 2 diabetes), to receive once-weekly subcutaneous Zepbound 5 mg, 10 mg, 15 mg, or placebo (1:1:1:1 ratio), including a 20-week dose-escalation period.SURMOUNT-1 SURMOUNT-1 was a 72-week, double-blind, placebo-controlled, phase 3 trial that randomized 2539 adult patients with a body mass index (BMI) of ≥30 kg/m 2 or ≥27 kg/m 2 and at least 1 weight-related comorbid condition (study excluded patients with type I diabetes or type 2 diabetes), to receive once-weekly subcutaneous Zepbound 5 mg, 10 mg, 15 mg, or placebo (1:1:1:1 ratio), including a 20-week dose-escalation period. Treatment was an adjunct to a reduced-calorie diet and increased physical activity.* Mean baseline body weight for Zepbound 5 mg was 226.8 lb, for Zepbound 10 mg 233.3 lb, for Zepbound 15 mg 232.8 lb, and for placebo 231.0 lb. 1-3 Coprimary endpoints were to demonstrate that Zepbound 10 mg and/or 15 mg are superior to placebo for mean percent change in body weight from baseline and percentage of study participants who achieved ≥5% body weight reduction at 72 weeks. 1,2
SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. … All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg).About SURMOUNT-1 and the SURMOUNT clinical trial program SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. Participants who had pre-diabetes at study commencement will remain enrolled in SURMOUNT-1 for an additional 104 weeks of treatment following the initial 72-week completion date to evaluate the impact on body weight and potential differences in progression to type 2 diabetes at three years of treatment with tirzepatide compared to placebo. All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg). The SURMOUNT phase 3 global clinical development program for tirzepatide began in late 2019 and has enrolled more than 5,000 people with obesity or overweight across six clinical trials, four of which are global studies. Results from SURMOUNT-2, -3, and -4 are anticipated in 2023.
About SURMOUNT-1 and the SURMOUNT clinical trial program SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. … All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg).Treatment discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) and 2.6% (placebo). The overall treatment discontinuation rates were 14.3% (5 mg), 16.4% (10 mg), 15.1% (15 mg) and 26.4% (placebo). The overall trial completion rates were 89% (5 mg), 88% (10 mg), 90% (15 mg) and 77% (placebo). About SURMOUNT-1 and the SURMOUNT clinical trial program SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. Participants who had pre-diabetes at study commencement will remain enrolled in SURMOUNT-1 for an additional 104 weeks of treatment following the initial 72-week completion date to evaluate the impact on body weight and potential differences in progression to type 2 diabetes at three years of treatment with tirzepatide compared to placebo. All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg). The SURMOUNT phase 3 global clinical development program for tirzepatide began in late 2019 and has enrolled more than 5,000 people with obesity or overweight across six clinical trials, four of which are global studies. Results from SURMOUNT-2, -3, and -4 are anticipated in 2023.
We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.Methods We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH.
Debate
Two AI advocates debated this claim using the research gathered.
Argument for
The claim is directly confirmed by the primary NEJM publication (Source 1), which states that 2539 adults were randomized 1:1:1:1 to once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, with the same design echoed in the original trial protocol (Source 3), the ClinicalTrials.gov registry (Source 20), and Nature Reviews Endocrinology (Source 2). Numerous independent post hoc analyses and secondary reports (Sources 6, 7, 10, 15, 19) consistently describe the identical dosing arms and 72-week duration, leaving no contradictory evidence in the brief.
The Proponent commits the fallacy of suppressed evidence by cherry-picking high-level summary phrasing from Source 1 (nejm.org) and Source 3 (cdn.clinicaltrials.gov) while omitting the explicit qualification in those very same sentences that the 72-week period included a 20-week dose-escalation phase starting at 2.5 mg (Source 6, pubmed.ncbi.nlm.nih.gov; Source 22, pubmed.ncbi.nlm.nih.gov). Furthermore, the Proponent's assertion that no contradictory evidence exists ignores Source 9 (nejm.org) and Source 20 (clinicaltrials.gov), which prove that the 1,032 participants with prediabetes actually received their assigned treatment for 176 weeks rather than stopping at 72 weeks.
Argument against
While the evidence largely describes a 72-week primary period at target doses of 5 mg, 10 mg, or 15 mg, the claim is strictly false because participants did not actually receive those specific doses for the entire 72-week duration, as all tirzepatide arms started at 2.5 mg and underwent a 20-week stepwise dose-escalation period via intermediate doses like 7.5 mg and 12.5 mg (Source 1, nejm.org; Source 7, pubmed.ncbi.nlm.nih.gov; Source 27, investor.lilly.com). Furthermore, the treatment duration in SURMOUNT-1 was not uniformly 72 weeks, because the 1,032 participants with prediabetes continued receiving their assigned doses for a total of 176 weeks rather than stopping at week 72 (Source 9, nejm.org; Source 20, clinicaltrials.gov).
The Opponent's first objection is a pedantic equivocation: the claim names the randomized assigned doses, and Source 1 itself describes the regimen as 5 mg, 10 mg, or 15 mg for 72 weeks 'including a 20-week dose-escalation period,' so escalation is part of the 72-week treatment rather than a contradiction of it. The second objection conflates the primary 72-week treatment period with an optional extension for prediabetic participants (Sources 9, 20, 21), which does not falsify the claim, since Source 20 and Source 13 explicitly define the main treatment period as 72 weeks and the claim never asserted that no participant continued beyond it.
Panel Review
3 reviewers assessed the evidence and the arguments.
Reviewer A · Claude
The primary NEJM publication (Source 1) states that 2539 adults were randomized 1:1:1:1 to once-weekly subcutaneous tirzepatide (5, 10 or 15 mg) or placebo for 72 weeks. The protocol (Source 3), the registry (Source 20) and many secondary analyses (Sources 2, 6, 7, 15, 19) say the same. The Opponent's objections do not defeat the claim. The 20-week dose escalation is explicitly part of the 72-week period in Source 1, and the claim describes the assigned doses. The 176-week extension for participants with prediabetes (Sources 9, 20) is an additional period beyond the primary 72-week treatment period, and the claim is about the primary phase. The claim is accurate as worded, with only trivial simplification.
Reviewer B · GPT
The primary peer-reviewed NEJM report directly states that SURMOUNT-1 was a phase 3 trial assigning participants to once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks, including a 20-week dose-escalation period [1]. The registered protocol independently specifies the same phase, dose arms, weekly regimen, subcutaneous administration, placebo comparator, and 72-week treatment period [3], while the trial registry identifies the study as SURMOUNT-1 and phase 3 [20]. The escalation from 2.5 mg and the longer extension for a prediabetes subgroup do not conflict with the claim, which accurately describes the randomized target-dose arms and the primary 72-week period without saying that every participant began at target dose or ceased all treatment at week 72. The claim is true as worded.
Reviewer C · Gemini
The claim verbatim describes the study design of the SURMOUNT-1 Phase 3 trial as reported in major peer-reviewed medical publications and regulatory study records. The primary trial report in The New England Journal of Medicine (Source 1) directly confirms that participants were randomly assigned to receive once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks. Other high-quality sources, including Nature Reviews Endocrinology (Source 2) and the study protocol (Source 3), confirm this exact wording and design for the primary trial period. The presence of a standard dose-escalation phase and an extended follow-up period for the prediabetes subpopulation are standard trial details that do not contradict the overall description of the trial.
Panel summary
The primary peer-reviewed NEJM report directly confirms every element of the claim: phase 3 design, once-weekly subcutaneous administration, 5 mg, 10 mg and 15 mg tirzepatide arms, placebo comparison, and a 72-week primary treatment period. The protocol and trial registry corroborate these details. The only qualification concerns how much detail the description requires: doses were escalated to assigned targets, and participants with prediabetes had a longer treatment extension. Neither detail contradicts the claim or changes the conclusion.